Naslov
GLP-1 receptor agonists: effects on nonalcoholic fatty liver disease

Autori
Bulum, Tomislav ; Blaslov Kristina ; Pavić Ljubičić, Antonela ; Duvnjak, Lea

Izvornik
Diabetologia Croatica (0351-0042) 43 (2014); 21-31

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
nonalcoholic fatty liver disease; fatty liver; glucagon-like peptide-1; liraglutide; exenatide

Sažetak
Nonalcoholic fatty liver disease (NAFLD), previously also named diabetes hepatitis, is characterized by accumulation of fat in the liver and refers to a spectrum of disorders ranging from simple hepatic steatosis to more severe manifestations including nonalcoholic steatohepatitis. Although the etiology is still unclear, NAFLD is strongly associated with hepatic and adipose tissue insulin resistance. Glucagon-like peptide 1 (GLP-1) receptor agonists represent a novel class of therapies for the treatment of type 2 diabetes with a potent blood glucose-lowering action mediated via its ability to induce insulin secretion and reduce glucagon secretion in a glucosedependent manner. In addition, GLP-1-based therapy has direct effects on decreasing hepatic steatosis invitro by modulating elements of the insulin signaling pathway via functional GLP-1 receptor, resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism, and the suppression of oxidative stress in liver cells.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA